publication date: Apr. 13, 2018
Issue 15 - Apr. 13, 2018
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Sharpless: Expect a big boost to NCI’s RPG pool

    NCI’s Research Project Grant pool is likely to receive the largest increase in funding in 16 years, NCI Director Norman “Ned” Sharpless said at an NCI Town Hall meeting April 10.

    The increase is made possible by a $3 billion raise to NIH’s budget that translates into $275 million in new money for the institute in fiscal year 2018.

  • Whistleblower suit claims McKesson repackaged, sold cancer drug “overfill”

    A whistleblower lawsuit alleges that McKesson Corp. had been repackaging cancer drugs and charging the federal and state governments for “overfill,” extra drug that is routinely put into vials by manufacturers.

  • In Brief

    • Gradishar named chief of hematology and Oncology at Northwestern
    • Cole named chief of pediatric hematology/oncology at Rutgers
    • ACS CAN report examines patient barriers to cancer clinical trial enrollment
    • Woodcock, Shaw and Conway-Welch receive awards from Society for Women’s Health Research
    • Billings appointed chief medical officer at Natera
  • Funding Opportunities

    DOD Ovarian Cancer Research Program Publishes funding opportunities

    FY18 OCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

  • TCCL Logo

  • Trials and Tribulations

    Sales Revenues at the Potential Expense of Patient Safety: The Example of You&i TM

    Ibrutinib is a selective and irreversible inhibitor of Bruton’s tyrosine kinase (BTK) that entered phase 1 clinical trials in 2009 based on preclinical efficacy in models of B-cell malignancy and autoimmune disease.[1, 2] The initial phase 1 trial showed clear efficacy in a number of lymphoid malignancies at doses as low as 1.25 mg/kg/d. Furthermore, full receptor occupancy was demonstrated at 2.5 mg/kg/d. Despite these pharmacological and early clinical findings, development of ibrutinib continued at doses of 420 mg qd and 560 mg qd, levels 3-4 fold higher than suggested by the pharmacological data. In addition, the absorption of ibrutinib is enhanced by administration of food, which may explain why even the lowest dose showed efficacy in some patients.

  • Clinical Roundup

    • NCI study revises molecular classification for most common type of lymphoma
    • Updated ASTRO guideline for lung radiation recommends concurrent chemotherapy for some stage III patients
    • Keytruda monotherapy meets OS endpoint in phase III trial
    • Epacadostat plus Keytruda don’t meet PFS endpoint in phase III study in metastatic melanoma
    • Roswell Park, Ohio State researchers identify genes linked to blood and marrow transplant outcomes
  • Drugs and Targets

    • Rucaparib approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    • FDA finalizes guidances to accelerate development of Next Gen sequencing
    • Karyopharm’s Selinexor receive FDA Fast Track designation
    • MD Anderson, Nanobiotix to collaborate on preclinical research combining NBTXR3, nivolumab

Copyright (c) 2018 The Cancer Letter Inc.